BAT Kenya Faces Delay in New Nicotine Pouch Product Launch

BAT by 2FIRSTS.ai
May.07.2024
BAT Kenya Faces Delay in New Nicotine Pouch Product Launch
BAT Kenya's new nicotine pouch production delayed due to lack of regulatory approval, impacting $23.7 million factory operations.

According to the African media outlet BusinessDaily Africa, on May 7, the Kenyan branch of the British American Tobacco Company (BAT) is unable to meet the growing demand for its new nicotine pouch product due to a lack of approval from regulatory authorities. This has resulted in a delay in the operation of their 2.5 billion Kenyan Shilling (approximately 23.7 million US dollars) factory, which was intended to produce new products for the African market.

 

BAT Kenya noted in its annual report that despite strong performance in the local market, the supply chain was disrupted at the end of last year due to the factory still not being operational.

 

BAT Kenya stated in a report that, "We plan to expedite the reduction of tobacco hazards in 2023 and reintroduce our nicotine pouch products in the Kenyan market by 2022. However, by the end of the year, our supply of nicotine pouches in the Kenyan market was disrupted due to regulatory uncertainty. This also affected the commercialization of our modern oral nicotine products manufacturing facility."

 

In 2019, the cigarette manufacturer BAT launched its nicotine pouch brand Lifyt in the Kenyan market for the first time. However, it was banned because it was classified as a pharmaceutical product rather than a tobacco product. The ban was lifted in 2022 after the nicotine pouches were agreed to be classified as tobacco products by the Tobacco Control Committee. BAT reintroduced the product to the market in 2023 under a new brand, Velo. Despite various pressures, the new nicotine pouch manufacturing facility is yet to be implemented.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
Phnom Penh “Mystery House” raided: authorities seize over 300,000 smoking devices and related items
Phnom Penh “Mystery House” raided: authorities seize over 300,000 smoking devices and related items
A Phnom Penh venue selling electronic smoking devices — nicknamed the “Mystery House” — was raided on the night of January 15, 2026, with authorities seizing over 300,000 items and arresting the 58-year-old owner. Seized evidence included smoking machines, cigarette heads, bottles of vape juice and marijuana grinding machines.
Jan.19 by 2FIRSTS.ai
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s customs data show vape (REL) excise revenue reached Rp 2.84 trillion in 2025 (≈$170.4 million), up 7.38% year over year. The gain came even as overall tobacco excise revenue declined. Minimum retail price benchmarks (HJE) for vape products rose in 2025, while excise rates remained unchanged from 2024; open-system e-liquids accounted for the largest share of revenue.
Jan.27 by 2FIRSTS.ai
UK Guernsey's QuitVape program for youth e-cigarette cessation to end at the end of the month
UK Guernsey's QuitVape program for youth e-cigarette cessation to end at the end of the month
QuitVape e-cigarette quitting service for teens in Guernsey to end this month, after six-month trial period.
Dec.29 by 2FIRSTS.ai
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai